At a glance
ClinicalIndex Comparison RecordN/ACompleted· 286 enrolled
Drug / intervention
Lyrica (pregabalin)drug
Likely dose
Lyrica (pregabalin) 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Jun 18, 2009·Updated Jan 25, 2021
In Brief
An observational study evaluating Lyrica (pregabalin) for Neuralgia and Epilepsy. Completed, enrolled 286 participants across 61 sites.
Detailed Summary
Clinical study with Lyrica (pregabalin) in patients suffering from epilepsy. This drug is used as adjunctive therapy with one or more antiepileptics. Lyrica has potential to reduce seizure frequency.
Study Details
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartSep 2009
Primary CompletionJun 2010
TodayJul 2026
First PostedJun 18, 2009
Enrollment StartSep 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.0 years ago
Interventions
Lyrica (pregabalin)drug
The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)